The use of hormonal therapy with radiotherapy for prostate cancer: Analysis of prospective randomised trials

British Journal of Cancer

Volumn 90, Issue 5, 2004, Pages 950-954

  Gottschalk, A R ^a   Roach III, M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Hormonal therapy; Prostate cancer; Radiation; Randomised trials; Whole pelvic radiation

Indexed keywords

ANDROGEN; ANTINEOPLASTIC AGENT; CYPROTERONE ACETATE; FLUTAMIDE; GOSERELIN; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN;

BEAM THERAPY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER HORMONE THERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; FOLLOW UP; GAMMA RADIATION; HORMONE INHIBITION; HUMAN; INTERMETHOD COMPARISON; META ANALYSIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CARCINOMA; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SHORT SURVEY;

ANTINEOPLASTIC AGENTS, HORMONAL; COMBINED MODALITY THERAPY; HUMANS; MALE; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS;

EID: 1942521069     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601625     Document Type: Short Survey

References (14)

1. Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Mattelaer J, Lopez Torecilla J, Pfeffer JR, Lino Cutajar C, Zurlo A, Pierart M (2002) Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360: 103-106
2. Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Gil T, Collette L, Pierart M (1997) Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337: 295-300
3. D'Amico AV, Keshaviah A, Manola J, Cote K, Loffredo M, Iskrytzky O, Renshaw AA (2002) Clinical utility of the percentage of positive prostate biopsies in predicting prostate cancer-specific and overall survival after radiotherapy for patients with localized prostate-cancer. Int J Radiat Oncol Biol Phys 53(3): 581-587
4. D'Amico AV, Schultz, Silver B, Henry L, Hurwitz M, Kaplan I, Bread CJ, Renshaw AA (2001) The clinical utility of the percent of positive prostate biopsies in predicting biochemical outcome following external-beam radiation therapy for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 49(3): 679-684
5. Hanks GE, Lu JD, Machtay M, Venkatesan VM, Pinover WH, Byhardt RW, Rosenthal SA (2000) RTOG protocol 92-02: a phase III trial of the use of long term total androgen supression following neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 48(3 Suppl 1): 112
6. Partin AW, Yoo J, Carter HB, Pearson JD, Chan DW, Epstein JI, Walsh PC (1993) The use of prostate specific antigen, clinical stage and Gleason score to predict pathologic stage in men with localized prostate cancer. J Urol 150: 110-114
7. Pilepich MV, Caplan R, Byhardt RW, Lawton CA, Gallagher MJ, Mesic JB, Hanks GE, Coughlin CT, Porter A, Shipley WU, Grignon D (1997) Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol 15: 1013-1021
8. Pilepich MV, Krall JM, al-Sarraf M, John MJ, Doggett RL, Sause WT, Lawton CA, Abrams RA, Rotman M, Rubin P, Shipley WU, Grignon D, Caplan R, Cox JD (1995) Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. Urology 45: 616-623
9. Pilepich MV, Winter K, John MJ, Mesic JB, Sause W, Rubin P, Lawton C, Machtay M, Grignon D (2001) Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 50: 1243-1252
10. Pilepich MV, Winter K, Lawton C, Krisch RE, Wolkov H, Movsas B, Hug E, Asbell S, Grignon D (2003) Phase III trial of androgen suppression adjuvant to definitive radiotherapy: long term results of RTOG study 85-31. Proc Am Soc Clin Oncol 22: 381
11. Roach M (1993) Equations for predicting the pathologic stage of men with localized prostate cancer using the preoperative prostate specific antigen (PSA) and Gleason score. J Urol 150: 1923-1924
12. Roach III M, DeSilvio M, Lawton C, Uhl V, Machtay M, Seider MJ, Rotman M, Jones C, Asbell SO, Valicenti RK, Han S, Thomas Jr CR, Shipley WS (2003) Radiation Therapy Oncology Group 9413. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol 21: 1904-1911
13. Roach M, Lu J, Pilepich MV, Asbell SO, Mohuidden M, Terry R, Grignon D, Lawton C, Shipley W, Cox J (2000b) Predicting long-term survival, and the need for hormonal therapy: a meta-analysis of the RTOG prostate cancer trials. Int J Radiat Oncol Biol Phys 47: 617-627
14. Roach M, Lu J, Pilepich MV, Asbell SO, Mohiuddin M, Terry R, Grignon D, Mohuidden M (2000a) Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on Radiation Therapy Oncology Group clinical trials. Int J Radiat Oncol Biol Phys 47: 609-615